New malaria vaccine offers better protection

Sanaria is grabbing headlines with its approach to fighting malaria. Researchers for the company have developed a process to create weakened parasites that create an immune response sufficient to protect 90 percent of patients for a 10-month period. The company's founder, Steven Hoffman, says that the vaccine could be a huge life saver in Africa. Malaria kills about two million people each year, and most of the victims are children.

- read the report from AHN

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.